Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673 https://t.co/jresR9MfXF https://t.co/flyfJob9un

• Preconceptional NSAID Treatment Exposure Is Associated with a Significantly Lon…

Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA: ❗Pre-conceptional NSAID use ❗Age Thought-provoking. Time to re-evaluate our NSAID prescribing practices for ♀️ SpA? #ACR22 @RheumNow ABST#1673 https://t.co/cHED0I3vUe

Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target. #ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I

L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow https://t.co/G31PrfqtVu

L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow

Does tofacitinib work better in patients with PsA and AS who smoke? Abstract #1036 #ACR22 @RheumNow 🚬519 ever smokers 🚭767 never smokers 💉In PsA only, TOF efficacy was greater in ever smokers vs. PBO ✋Overall, efficacy was generally comparable in ever v. never 🚬

Abstract #PP25 Patient mantra on life with SpA: “not to over-exert the body on your good days and always strive to be active on your bad days” Patient recommended exercise: 🏓table tennis 🏊‍♂️swimming 🧘yoga 🤸tai chi #ACR22 @RheumNow